Servier’s EU Nightmare Continues As Commission Moves To Shut Down Disputed IP Practices
This article was originally published in The Pink Sheet Daily
The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.
You may also be interested in...
The EU Commission's assumption that pharma pay-for-delay settlements are anti-competitive is by no means water-tight, a senior IP and competition lawyer suggests.
The European Commission has published its fourth report in monitoring patent settlements, but again has failed to offer pharma companies guidance on how to avoid potential competition abuses.
The European Commission decides to fine Lundbeck and a number of generic drug manufacturers for conspiring to delay the entry of generic citalopram onto the market, but the final outcome of the case could not be decided for several years.